ArticleCureus2024
Jejunal Gastrointestinal Stromal Tumor: A Rare, Elusive, and Formidable Cause of Obscure Bleeding.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chasing Down the Bleed: A Jejunal Gastrointestinal Stromal Tumor Missed for Nearly a Decade and Treated With Argon Plasma Coagulation.ACG case reports journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal bleeding is classified as obscure in 5% of patients who remain symptomatic after undergoing upper endoscopy, colonoscopy, and small bowel capsule endoscopy. We present a case of a 45-year-old male who had obscure bleeding for eight years and presented with hemorrhagic shock. He was found to have an ulcerated intra-luminal jejunal lesion on enteroscopy, then had surgical resection that revealed a low-risk gastrointestinal stromal tumor (GIST). If GISTs are bleeding, hemostasis should first be achieved with medical, endoscopic, or radiologic interventions, and then resected because they can have malignancy potential. Furthermore, they should be risk-stratified and either surveilled to monitor for recurrence if low risk or need adjuvant imatinib if high risk. There are currently no screening guidelines for GISTs despite their increasing incidences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.